C17 - What Do I Do Now?: Neurologic Consultations in Cancer Patients II
| Event Time: | Saturday May 4, 2019 9:30 am to 11:30 am |
| Topic(s): | Neuro-oncology |
| Director(s): | Patrick Wen MD, FAAN |
| Description: | Recently there has been significant progress in the treatment of cancer with novel targeted therapies and immunotherapies. These agents can be associated with significant neurologic complications. In addition, there is also increasing recognition of neurologic complications that can occur in cancer patients, including paraneoplastic syndromes. Using cases, faculty will present an overview of the neurologic complications of novel cancer therapies, including immunotherapies, as well as neurologic complications of cancer, including neurologic paraneoplastic disease. This program complements What Do I Do Now?: Neurologic Consultations in Cancer Patients I, but covers independent topics. |
| Completion Message: | Participants should be able to recognize the complications of novel targeted molecular therapies and immunotherapies, including checkpoint inhibitors and CAR-T-cell therapies. They will also recognize and be able to manage neurologic complications of cancer, including paraneoplastic syndromes. |
| CME Credits: | 2 |
| Core Competencies: | Patient Care, Medical Knowledge, Practice-based Learning and Improvement |
| Start/End Time | Title | Faculty |
|---|---|---|
| 9:30 AM - 10:10 AM | Neurologic Complications of Novel Cancer Therapies, Including Immunotherapies | Patrick Y. Wen MD, FAAN |
| 10:10 AM - 10:50 AM | Paraneoplastic Neurologic Syndromes | Josep O. Dalmau MD, PhD, FAAN |
| 10:50 AM - 11:30 AM | Case Studies | Amy A. Pruitt MD, FAAN |
| Speaker | Disclosure |
|---|---|
| Josep O. Dalmau, MD, PhD, FAAN | Dr. Dalmau has received personal compensation in an editorial capacity for Editor: Neurology, Neuroimmunology, Neuroinflammation; and UpToDate. Dr. Dalmau has received royalty, license fees, or contractual rights payments from Euroimmune. Dr. Dalmau has received research support from Sage therapeutics. |
| Amy A. Pruitt, MD, FAAN | Dr. Pruitt has nothing to disclose. |
| Patrick Y. Wen, MD, FAAN | Dr. Wen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Abbvie, AstraZeneca, Roche, Ziopharm, Vascular Biogenics, Ziopharm, Taiho, Tocagen, Puma. Dr. Wen has received personal compensation in an editorial capacity for Neuro-Oncology, UpToDate, Elsevier. |
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C5 -
What Do I Do Now?: Neurologic Consultations in Cancer Patients I
Jaishri Blakeley MD |
| 9:30 AM-11:30 AM |
| 7:00 AM-9:00 AM |
|---|
|
C41 -
Neuro-oncology in 2019: Navigating Current Trends
Maciej Mrugala MD, PhD, MPH, FAAN |
| 9:15 AM-12:00 PM |
|
Presidential Plenary Session
Natalia Rost MD, MPH, FAAN, FAHA |
| 11:30 AM-6:30 PM |
|
P1 -
Poster Session 1
|
| 3:30 PM-5:30 PM |
|
C69 -
The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders
Tobias Walbert MD, PhD |
| 4:45 PM-5:30 PM |
|
Neuro-oncology Section Guided Poster Tour
|
| 7:00 AM-9:00 AM |
|---|
|
C81 -
Core Principles of Brain Tumors
Nimish Mohile MD, FAAN |
| 11:30 AM-6:30 PM |
|
P2 -
Poster Session 2
|
| 1:00 PM-3:00 PM |
|
S14 -
Translational and Clinical Advances in Neuro-oncology
|
| 3:30 PM-5:30 PM |
|
C110 -
Adult and Pediatric Neuro-Oncology for the Neurohospitalist
Na Tosha Gatson MD, PhD |
| 9:15 AM-11:30 AM |
|---|
|
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
| 11:30 AM-6:30 PM |
|
P3 -
Poster Session 3
|
| 3:30 PM-5:30 PM |
|
S30 -
Brain Cancer: From Epidemiology to Quality of Life
|
| 1:00 PM-3:00 PM |
|---|
|
C178 -
Therapy in Neurology I: Neurological Infectious Diseases and Neuro-oncology
Madhu Soni MD, FAAN |
| 2:00 PM-2:30 PM |
|---|
|
Choosing a Career in Neuro-oncology
Sylvia Kurz MD, PhD |